Stocks · News reference
Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DexCom, Inc. announced that its G7 15-day continuous glucose monitoring (CGM) system will be available in Canada starting in November 2026 for adults aged 18 and older.
Leerink Partners has lowered its price target for DexCom, Inc. from $94 to $87.
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.
Dexcom's CONNECT trial results, published in The New England Journal of Medicine, demonstrate that its G7 continuous glucose monitoring system achieves a 1.6% A1C reduction in non-insulin-treated Type 2 diabetes patients, with 97% adherence at 26 weeks. The findings support broader CGM adoption and could expand market opportunities, though success depends on physician adoption and insurance coverage. The global CGM market is projected to grow from $13.4 billion in 2025 to $41.4 billion by 2033.